Atrial fibrillation in the elderly

British Journal of Cardiology

Volumn 10, Issue 5, 2003, Pages 373-378

  Berry, Colin ^a   Rae, Allan ^a   Taylor, Jaqueline ^a   Brady, Adrian J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Anticoagulation; Atrial fibrillation; Elderly; Radiofrequency ablation; Rate control; Rhythm control

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; DIGITALIS GLYCOSIDE; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; ESMOLOL; FLECAINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPAFENONE; SOTALOL; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ARTIFICIAL HEART PACEMAKER; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONSTIPATION; DEATH; DIARRHEA; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG TOLERABILITY; ELDERLY CARE; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; LETHARGY; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0142246922     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001;22:1852-923.
2. Fan W, Peter Ct, Gang Es, Mandel W. Age-related-changes in the clinical and electrophysiologic characteristics of patients with Wolff-Parkinson-White syndrome - Comparative study between young and elderly patients. Am Heart J 1991;122:741-7.
3. Brembilla-Perrot B, Holban I, Houriez P, Claudon O, Beurrier D, Vancon AC. Influence of age on the potential risk of sudden death in asymptomatic Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiology 2001;24:1514-18.
4. Brembilla-Perrot B, Holban I, Houriez P, Beurrier D, Claudon O, Vancon AC. Does age influence the indications for investigating asymptomatic Wolff-Parkinson-White syndrome? Arch Mal Coeur Vaiss 2000;93:1523-7.
5. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial-fibrillation - The Framingham-Study. N Engl J Med 1982;306:1018-22.
6. Baine WB, Yu W, Weis KA. Trends and outcomes in the hospitalization of older Americans for cardiac conduction disorders or arrhythmias, 1991-1998. J Am Geriatr Soc 2001;49:763-70.
7. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-41.
8. Gerdts E, Oikarinen L, Palmieri V et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy - The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Hypertension 2002;39:739-43.
9. Kaplan BM, Langendorf R, Lev M et al. Tachycardia-bradycardia syndrome (so called 'sick sinus syndrome'). Am J Cardiol 1973;26:497-508.
10. Berry C, Stewart S, Payne EM, McArthur JD, McMurray JJV. Electrical cardioversion for atrial fibrillation: Outcomes in 'real-life' clinical practice. Int J Cardiol 2001;81(1):29-35.
11. Consensus Panel. Consensus conference on the management of atrial fibrillation in hospital and general practice. Proc Roy Coll Phys (Edinburgh) 1998;28:552-4.
12. Stewart S, MacIntyre K, MacLeod MMC, Bailey AEM, Capewell S, McMurray JJV. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J 2001;22:693-701.
13. Sabatini T, Frisoni GB, Barbisoni P, Bellelli G, Rozzini R, Trabucchi M. Atrial fibrillation and cognitive disorders in older people. J Am Geriatr Soc 2000;48:387-90.
14. Ott A, Breteler MMB, DeBruyne MC, VanHarskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study - The Rotterdam Study. Stroke 1997;28:316-21.
15. O'Connell JE, Gray CS, French JM, Robertson IH. Atrial fibrillation and cognitive function: Case-control study. J Neurol Neurosurg Psychiatry 1998;65:386-9.
16. Ezekowitz MD, James KE, Nazarian SM et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation 1995;92:2178-82.
17. Raiha I, Tarvonen S, Kurki T, Rajala T, Sourander L. Relationship between vascular factors and white matter low attenuation of the brain. Acta Neurol Scand 1993;87:286-9.
18. Chimowitz MI, Degeorgia MA, Poole RM, Hepner A, Armstrong WM. Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. Stroke 1993;24:1015-119.
19. Wolf PA. Atrial fibrillation - A major contributor to stroke in the Framingham population. Arch Intern Med 1987;147:1561-4.
20. Wolf PA. Atrial fibrillation as an independent risk factor for stroke. Stroke 1991;22:983-8.
21. Wolf PA. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-34.
22. Petersen P. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987;18:1098-100.
23. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology 1978;28:973-7.
24. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. Circulation 1998;98:946-52.
25. Stewart S, MacIntyre K, Chalmers JWT et al. Trends in case fatality in 22,968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. Int J Cardiol 2002;82:229-36.
26. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998;82(8A):2N-8N.
27. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
28. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 2002;16:741-51.
29. Marshall H, Harris Z, Griffith M et al. Prospective randomised study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation. Effects of pacing mode and mode-switch algorithm. Circulation 1999;99:1587-92.
30. Pappone C, Rosanio S. Chronic atrial fibrillation in an 80-year-old patient. In: Brugada J (ed.) Atrial Fibrillation - A Practical Approach. Barcelona: Prous, 2002: 49-53.
31. Laupacis A, Boysen G, Connolly S et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial-fibrillation - Analysis of pooled data from 5 randomised controlled trials. Arch Intern Med 1994;154:1449-57.
32. Ezekowitz MD, Netrebko PI. Anticoagulation in management of atrial fibrillation. Curr Opin Cardiol 2003;18(1):26-31.
33. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med 2002;162:541-50.
34. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001;161:2125-8.
35. Berry C, McMurray J. Anticoagulation for patients with atrial fibrillation Warfarin should be given for up to one year after successful cardioversion. BMJ 2000;321(7261):639.
36. Eriksson UG. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003;59(1):35-43.